Suzhou Gracell Biotechnologies

Gracell Biotechnologies is a clinical-stage biopharmaceutical company specializing in the development of innovative cell therapies for the treatment of cancer and autoimmune diseases. The company utilizes its proprietary FasTCAR and TruUCAR platforms to overcome industry challenges such as long manufacturing times, high costs, and limited efficacy of conventional CAR-T therapies. Its lead candidate, GC012F, is a dual-targeting BCMA/CD19 CAR-T therapy being evaluated for multiple myeloma and systemic lupus erythematosus. In early 2024, Gracell was acquired by AstraZeneca to bolster its cell therapy pipeline and manufacturing capabilities. The company operates research and manufacturing facilities in both China and the United States.